TP53 and cancer: This is discussed in detail in the publication centred on the molecular pathology/genomics aspects of the cohort [10], though an overall impression of the rates of gene mutations using our TruSeqTM cancer gene panel is depicted in Figure 3B where it is observed that not unexpectedly, TP53 is the most frequently mutated gene within our solid cancer sample collection from phase 1.